MediWound Ltd. (NASDAQ:MDWD) Q3 2024 Earnings Conference Call November 26, 2024 8:30 AM ET
Company Participants
Dan Ferry - IR, LifeSci Advisors
Ofer Gonen - Chief Executive Officer
Hani Luxenburg - Chief Financial Officer
Barry Wolfenson - Executive Vice President, Strategy & Corporate Development
Conference Call Participants
Josh Jennings - Cowen
Swayampakula Ramakanth - H.C. Wainwright
Michael Okunewitch - Maxim Group
Operator
Good day, and welcome to the MediWound Third Quarter 2024 Earnings Call. All participants will be in a listen-only mode. [Operator Instructions] Please note, this event is being recorded.
I would now like to turn the conference over to Mr. Dan Ferry of LifeSci Advisors. Please go ahead, sir.
Dan Ferry
Thank you, operator, and welcome, everyone.
Today, before the market open, MediWound issued a press release announcing financial results for the third quarter ended September 30, 2024. You may access that release on the company's website under the Investors tab.
With us today are Ofer Gonen, Chief Executive Officer of MediWound; Hani Luxenburg, Chief Financial Officer; and Barry Wolfenson, Executive Vice President of Strategy and Corporate Development. Following our prepared remarks, we will open the call for Q&A.
Before we begin, I would like to remind everyone that statements made during this call, including the Q&A session, relating to MediWound's expected future performance, future business prospects or future events or plans are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. Although the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, actual outcomes and results are subject to risks and uncertainties and could differ materially from those forecast due to the impact of many factors beyond the control of MediWound.
The company assumes no obligation to update or supplement any forward-looking statements, whether as a result of new information, future events or otherwise. Participants are directed to cautionary notes set forth in today's press release as well as the risk factors set forth in MediWound's annual report filed with the SEC for factors that could cause actual results to differ materially from those anticipated in the forward-looking statements.
The conference call is the property of MediWound, and any recording or rebroadcast is expressly prohibited without the written consent of MediWound.
Now, I would like to turn the call over to Ofer Gonen, Chief Executive Officer of MediWound. Ofer?
Ofer Gonen
Thank you, Dan, and good morning, everyone. I appreciate you joining us today to discuss MediWound's performance and progress during the third quarter of 2024.